CAS: 339186-68-4 - Matuzumab
Formula:Unspecified
- Synonyms:
- Emd 62000
- Emd 7200
- Emd 72000
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal 425 γ1-chain), disulfide with human-mouse monoclonal 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (humanized MAb 425 γ1-chain), disulfide with humanized MAb 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor)(humanized MAb 425 gamma-1 chain), disulfide with humanized MAb 425 kappa-chain, dimer
- KGaA
- Matuzumab [INN]
- Merck KGaA
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Matuzumab REF: TM-T9922CAS: 339186-68-4 | 98% | 541.00 € | Mon 15 Jul 24 |
 | Matuzumab - 10 mg/ml REF: 3D-BM165590CAS: 339186-68-4 | Min. 95 Area-% | 1,134.00 €~1,742.00 € | Thu 25 Jul 24 |
Matuzumab
CAS:339186-68-4
Matuzumab: a humanized monoclonal antibody targeting EGFR to inhibit cancer growth.
Purity:
98%
Color and Shape:
Solid
Molecular weight:
N/A
Ref: TM-T9922
| 5mg | 541.00 € |
Estimated delivery in United States, on Monday 15 Jul 2024
Matuzumab - 10 mg/ml
CAS:339186-68-4
Intereferes with EGFR homodimerisation; cancer therapy
Purity:
Min. 95 Area-%
Color and Shape:
Powder
Ref: 3D-BM165590
| 1mg | 1,134.00 € | ||
| 2mg | 1,395.00 € | ||
| 5mg | 1,742.00 € |
Estimated delivery in United States, on Thursday 25 Jul 2024
